Please view this page on a desktop or larger tablet device for the full functionality.

Quotient Case Study device preview

Quotient Sciences

Healthcare Specialists: Investment in a high growth market leader with unique service

Identified a unique business operating a differentiated, innovative and premium offering in a large and otherwise commoditized marketplace

Addressing an industry demand for faster, more efficient drug development and desire for full-service capabilities

A UK only business with global potential – delivering drug development services with highly specialized competencies

Quotient Clinical logo
  • December 2015
  • UK only
  • Unique CDMO + CRO service offering
  • 270 employees

Better, faster, more accessibile:
Translational Pharmaceutics

More Efficient

Saves 3-6 months from clinical development

  • Manufacture
  • Formulate
  • Dose
  • Pharmacology
  • CDMO
  • CRO

Lower Cost

Estimated €50m saved per molecule

GHO Value Creation: Enablement & Alignment

Implement strategy of following molecules through their development lifecycle

  • Operating footprint
  • Access new clients
  • Deepen relationships
  • Access new talent pool
Map 1
Translational Pharmacuetics® Translational New and repeat clients / new molecules

Unique platform to win new clients and molecules

Wins molecules and follow them through clinical trial supply and commercial manufacturing

Formulation Development New and repeat clients / new molecules
Clinical Trial Manufacturing High barriers to exit and revenue longevity
Scale-up and Commercial Manufacturing Embedded customers revenue longevity (multi-year)

Quotient is best placed to continue to manufacture drug products

Win molecules and follow them through clinical trial supply and commercial manufacturing

Building Strategic Footprints

CDMO services

Placeholder image

CDMO based in the UK

Expertise in taste making especially for OTC and in paediatric development services

Performs all types of dosage form

Identified pre Quotient completion

CRO services

Placeholder image

Clinical pharmacology capabilities based in Florida

Required to execute TP in the US as well as to provide full service capabilities

Acquired from founders; originated and executed by GHO

CDMO services

Placeholder image

CDMO based in Pennsylvania

Focus on high potency products

Provides manufacturing for the US TP and commercial manufacturing - following the molecule

Complex carve-out sourced and executed by GHO

CDMO services

Placeholder image

CDMO based in the UK

Expansion into preclinical formulation development through to clinical trial supplies

Added 48,000 sq. ft. facility to production network freeing up Nottingham capcity for TP

Carve-out led by GHO

Delivering strategic footprint

Capability Service
Scale International Capability Capacity Service
Scale International Capability Capacity Service
Capability Capacity Service

Capability & Capacity

Placeholder image


  • Flexible working patterns
  • Taken on new lease in FY20 for new 28,000 sq.ft building to relocate all clinical operations
  • Shifting CTM activity to Reading provides additional TP capacity
Placeholder image


  • Quadrupled the site's GMP capacity in FY19 by adding 10 new GMP suites, giving a total of 13 suites for oral solid and inhaled dose manufacturing (--EI .5m investment)
  • Expansion of analytical labs and office areas planned in FY21 to support an increased number of GMP suites
Placeholder image

Chelsea Parkway

  • Transitioning to late stage / commercial facility only
  • Flexible operating environment; equipment can be moved from suite to suite
  • Part ofthe current facility only runs one shift per day, five days per week. Potential to increase capacity by implementing two or three shifts as volume and demand increases
Placeholder image

Garnet Valley

  • Recently built (January 2019) state-of-the-art facility dedicated to early stage C TM and TP in the IJS, located two miles from the Chelsea Parkway facility (—EI 2m investment)
  • Formulation and analytical labs to be added in FY20 (18,000 sq.ft) included in plan
  • 6 further GMP suites possible in remaining 4,500 sq.ft available space
Placeholder image


  • Facility improvements planned in F Y 20 to upgrade the pharmacy and move the screening facility closerto the clinic included in budget
  • Fewer beds per study required in TP vs. Clin Pharm studies (i.e. capacity to support growth)
Placeholder image


  • GHO upgraded facility to increase quality of workspace
  • Office based facility (plus home workers)

5 sites

Placeholder image

State-of-the-art facilities

>850 employees

Placeholder image

Deep scientific knowledge

Formulation and drug delivery

Placeholder image

All types of dosage form

Clinical trial manufacturing

Placeholder image

High potency capabilities

2 clinical pharmacology centres

Placeholder image

280 beds globally

Commerical manufacturing

Placeholder image

Niche and hard to make products

Translational Pharmaceuticals

Placeholder image

Proven to save money

Transatlantic Platform: Globally differentiated pharmaceutical drug development service provider

4 add ons

+200 molecules

+580 employees

3x order book

+150 clients

2x Continental Footprint

Subscribe to our email alerts

Email updates